UNLABELLED: FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FRAX®-defined MOF compared with those treated with risedronate. INTRODUCTION: The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX®-defined major osteoporotic fractures (MOF), which include clinical vertebral, hip, humerus, and forearm fractures. METHODS: In total, 1360 postmenopausal women (mean age 72.1 years) were randomized to receive subcutaneous daily teriparatide (20 μg) or oral weekly risedronate (35 mg). Patient cumulative incidence of ≥ 1 FRAX®-defined MOF and of all clinical fractures were estimated by Kaplan-Meier analyses, and the comparison between treatments was based on the stratified log-rank test. Additionally, an extended Cox model was used to estimate HRs at different time points. Incidence fracture rates were estimated at each 6-month interval. RESULTS: After 24 months, 16 (2.6%) patients in the teriparatide group had ≥ 1 low trauma FRAX®-defined MOF compared with 40 patients (6.4%) in the risedronate group (HR 0.40; 95% CI 0.23-0.68; p = 0.001). Clinical vertebral and radius fractures were the most frequent FRAX®-defined MOF sites. The largest difference in incidence rates of both FRAX®-defined MOF and all clinical fractures between treatments occurred during the 6- to 12-month period. There was a statistically significant reduction in fractures between groups as early as 7 months for both categories of clinical fractures analyzed. CONCLUSION: In postmenopausal women with severe osteoporosis, treatment with teriparatide was more efficacious than risedronate, with a 60% lower risk of FRAX®-defined MOF during the 24-month treatment period. Fracture risk was statistically significantly reduced at 7 months of treatment. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.

Centro Paulista de Investigaçao Clínica Sao Paulo Brazil

CHU Brugmann Université Libre de Bruxelles Brussels Belgium

Division of Endocrinology and Diabetology Medical University of Graz Graz Austria

Institut Präventive Medizin and Klinische Forschung Magdeburg Germany

Institute of Rheumatology and Faculty of Medicine 1 Charles University Prague Czech Republic

Lilly Research Center Europe Madrid Spain

Maastricht University Medical Center Maastricht The Netherlands

Regional Hospital University of Orleans Orleans France

Sapienza Rome University Rome Italy

University Hospital Parc Taulí Sabadell Barcelona Spain

University of British Columbia Vancouver Canada

Zobrazit více v PubMed

Kendler D, Marin F, Zerbini C, Russo L, Greenspan S, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body J, Geusens P, Möricke R, Lopez-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240. doi: 10.1016/s0140-6736(17)32137-2. PubMed DOI

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397. doi: 10.1007/s00198-007-0543-5. PubMed DOI PMC

Miller P, Hattersley G, Riis B, Williams G, Lau E, Russo L, Alexandersen P, Zerbini C, Hu M, Harris A, Fitzpatrick L, Cosman F, Christiansen C. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733. doi: 10.1001/jama.2016.11136. PubMed DOI

Saag K, Petersen J, Brandi M, Karaplis A, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner P, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. doi: 10.1056/NEJMoa1708322. PubMed DOI

Strom O, Borgstrom F, Kanis J, Compston J, Cooper C, McCloskey E, Jonsson B. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2011;6:59–155. doi: 10.1007/s11657-011-0060-1. PubMed DOI

European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. London, 16 November 2006. Doc. Ref. CHMP/EWP/552/95 Rev.2

Genant H, Wu C, van Kuijk C, Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–1148. doi: 10.1002/jbmr.5650080915. PubMed DOI

Hadji P, Zanchetta J, Russo L, Recknor C, Saag K, McKiernan F, Silverman S, Alam J, Burge R, Krege J, Lakshmanan M, Masica D, Mitlak B, Stock J. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141–2150. doi: 10.1007/s00198-011-1856-y. PubMed DOI

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J, Hodsman A, Eriksen E, Ish-Shalom S, Genant H, Wang O, Mellström D, Oefjord E, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki A, Mitlak B. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi: 10.1056/nejm200105103441904. PubMed DOI

Saag K, Shane E, Boonen S, Marín F, Donley D, Taylor K, Dalsky G, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039. doi: 10.1056/NEJMoa071408. PubMed DOI

McCloskey E, Johansson H, Oden A, Harvey N, Jiang H, Modin S, Fitzpatrick L, Kanis J. The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res. 2017;32(8):1625–1631. doi: 10.1002/jbmr.3163. PubMed DOI PMC

Diez-Perez A, Marin F, Eriksen E, Kendler D, Krege J, Delgado-Rodriguez M. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone. 2019;120:1–8. doi: 10.1016/j.bone.2018.09.020. PubMed DOI

Kanis J, Harvey N, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee J, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12. doi: 10.1007/s00198-019-05176-3. PubMed DOI PMC

Lindsay R, Miller P, Pohl G, Glass E, Chen P, Krege J. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(6):943–948. doi: 10.1007/s00198-008-0766-0. PubMed DOI

Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E, Sigurdsson G, Kanis J. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775–780. doi: 10.1007/s00198-016-3868-0. PubMed DOI PMC

Geusens P, Marin F, Kendler D, Russo L, Zerbini C, Minisola S, Body J, Lespessailles E, Greenspan S, Bagur A, Stepan J, Lakatos P, Casado E, Moericke R, Lopez-Romero P, Fahrleitner-Pammer A. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of ostmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res. 2018;33(5):783–794. doi: 10.1002/jbmr.3384. PubMed DOI

Roux C, Seeman E, Eastell R, Adachi J, Jackson R, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts N. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20(4):433–439. doi: 10.1185/030079903125003125. PubMed DOI

Siris E, Genant H, Laster A, Chen P, Misurski D, Krege J. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18(6):761–770. doi: 10.1007/s00198-006-0306-8. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01709110